Myogen darusentan to enter Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Myogen plans to move its selective endothelin receptor antagonist darusentan into Phase III for resistant hypertension following significant Phase II results, the firm says Aug. 18. In a 115-patient placebo-controlled trial, darusentan showed significant reductions of 11.6 mmHg (p=0.02) in systolic blood pressure and 7.0 mmHg (p<0.001) in diastolic blood pressure. Myogen is highlighing darusentan's mechanism of action as "different than those of currently approved antihypertensive drugs." Myogen shares rose more than 60% upon announcement of the results...